Listed

3D Systems Corp: Form 10-Q for the period ended Sep 30, 2023

Filed with the SEC on Nov 9, 2023 and accepted by EDGAR at Nov 9, 2023, 16:10 ET.

Share

Management's discussion and analysis

As filed, 96,362 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis should be read together with our unaudited condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly Report on Form 10-Q (the “Financial Statements”). Certain statements contained in this discussion may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that may affect our future performance, as discussed in greater detail under the heading “Forward Looking Statements” below and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 (“2022 Form 10-K”).

Business Overview

3D Systems Corporation (“3D Systems” or the “Company” or “we,” “our” or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and the Asia Pacific and Oceania regions (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and digital design tools. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions and Industrial Solutions. We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.

The Company has two reportable segments, Healthcare Solutions and Industrial Solutions. Healthcare Solutions includes dental, medical devices, personalized health services and regenerative medicine. Industrial Solutions includes aerospace, defense, transportation and general manufacturing. We architect solutions specific to customers’ needs through a combination of materials, hardware platforms, software, professional services and advanced manufacturing – creating a path to integrating additive manufacturing into traditional production environments. As a result, manufacturers achieve design freedom, increase agility, scale production and improve their overall total cost of operation. Our technologies and process knowledge enable over a million production parts to be made through additive manufacturing each day.

Recent Developments

Fiscal Year 2023 Restructuring Activity

On May 8, 2023, the Company announced its plans to reduce its headcount by approximately 6%, with the majority of reductions being made in corporate and business support functions predominantly located in the US and Europe. The reduction in headcount, which resulted in the recognition of $3.0 million of severance-related costs, was part of the Company’s multi-faceted restructuring initiative that has also included the Company’s plans to in-source the manufacturing of certain metal printer platforms, as previously announced during the quarter ended March 31, 2023. The headcount reduction announced during our second fiscal quarter of 2023, reflected both our plan to improve operating efficiencies and investments that we had made to improve business processes, rationalize operations, and integrate the acquisitions completed over the past two years. Our plan to in-source certain metal printer platforms is expected to improve cycle time from development to production by co-locating the engineering and manufacturing related to such platforms. The combination of reducing the Company’s headcount and the in-sourcing of certain metal printer platforms as part of this phase of the Company’s restructuring initiative is expected to result in (1) total reduced operating expenses of between $4.0 million and $6.0 million for the fiscal year ending December 31, 2023 and (2) reduced operating expenses of between $9.0 million and $11.0 million for future annual periods, beginning with the fiscal year ending December 31, 2024.

On October 25, 2023, the Company announced the latest phase of its multi-faceted restructuring initiative, which is expected to continue to improve operating efficiencies throughout the organization and drive long-term value creation. This additional phase of the restructuring initiative will target the delivery of incremental annualized savings of between $45.0 million and $55.0 million by the end of the fiscal year ended December 31, 2024, with the majority of the cost takeout to occur by the end of the first quarter of 2024. The initiative is primarily targeted at continuing to rationalize headcount, as well as rationalizing geographic locations, across all functions of the Company. The initiative also considers strategic actions expected to be taken with respect to certain of the Company’s previously acquired businesses. (Refer to the discussion below at “Acquisitions/Investments” for additional detail.)

Stratasys Update

Since June 2023, the Company has delivered to the board of directors of Stratasys Ltd. (“Stratasys”) multiple proposals to acquire all of Stratasys’ issued and outstanding ordinary shares of common stock. On September 6, 2023, the Company delivered its most recent proposal to Stratasys and on September 13, 2023 delivered in escrow a binding merger agreement (the “Merger Agreement”) and an accompanying escrow letter (the “Escrow Letter”), for the acquisition of 100% of Stratasys’ issued and outstanding shares of common stock for a per share consideration equivalent of (1) $7.00 in cash and (2) 1.6387 newly issued shares of the combined company. The Company’s binding offer expired on October 5, 2023 with no further engagement from Stratasys. Refer to the Company’s Form 8-K furnished on September 13, 2023 for additional details regarding the Company’s most recent proposal for the acquisition of Stratasys.

Acquisitions/Investments

The Company has made the following significant acquisitions and investments, commencing with the fourth quarter of 2021 and continuing through September 30, 2023.

Wematter AB

On July 1, 2023, the Company completed the acquisition of Wematter AB (“Wematter”), a Swedish 3D printer manufacturer. The acquisition broadens 3D Systems’ Selective Laser Sintering (SLS) portfolio. Consideration for this acquisition consisted of approximately $10,224 in cash, subject to customary post-closing adjustments. The Company also may be required to pay an additional €2,000 in cash, contingent upon the achievement of certain post-closing performance conditions and the continued employment of certain Wematter key employees for two years after the closing date. If earned, the €2,000 is expected to be recognized as compensation expense over the two-year service period that the key employees must remain employed at 3D Systems. As of September 30, 2023, management believes that the achievement of the post-closing performance conditions is probable and has commenced the recognition of the compensation expense accordingly.

Theradaptive, Inc.

In June of 2023, we made an $8.0 million investment in Theradaptive, Inc. ("Theradaptive"), via the purchase of Series A Preferred Stock, pursuant to which we hold an approximate 9.15%, or 8.25% fully-diluted, ownership interest in Theradaptive. Theradaptive is currently developing a protein that encourages bone growth. This biotechnology could be applied to 3D printed metal splints for patients who otherwise may require amputation of a limb because the lost bone is too vast to replace with a splint. The Company has accounted for its investment in Theradaptive on a cost basis, subject to assessment for impairment, as the fair value of Theradaptive's equity is not readily determinable and the investment is not subject to the equity method of accounting due to the Company's lack of significant influence. The investment in Theradaptive is not expected to materially impact our future financial position, results of operations, or cash flows.

dp polar GmbH

On October 4, 2022, we completed the acquisition of dp polar GmbH ("dp polar"), a German-based designer and manufacturer of a manufacturing system designed for true high-speed mass production of customized components, for $25.9 million, which includes $19.6 million paid in cash at closing, $7.1 million paid at closing via the issuance of the Company’s common stock, and a provisional estimated post-closing purchase price adjustment of $0.8 million due to the Company from the sellers. An additional payment of $2.2 million, consisting of the issuance of 249,865 shares of the Company’s common stock, could be required if a key individual from dp polar's management team provides service to the Company through December 31, 2024. dp polar has not yet begun to generate revenues and, accordingly, the acquisition’s impact on the Company’s results of operations and cash flows has been dilutive.

Kumovis GmbH

On April 1, 2022, we completed the acquisition of 93.75% of Kumovis GmbH ("Kumovis") for an all-cash purchase price of $37.9 million. $3.6 million of the purchase price was deferred for up to fifteen months from the closing date, and was paid in July 2023. Kumovis, which is part of the Healthcare Solutions segment, utilizes polyether ether keton or “PEEK” materials, which have properties that lend it to many medical applications, including many implant applications, that fit into our personalized healthcare solutions operations. The acquisition’s near-term impact on the Company's results of operations and cash flows has been dilutive.

Titan Additive LLC

On April 1, 2022, we completed the acquisition of 100% of Titan Additive LLC ("Titan") for an all-cash purchase price of $39.0 million. Titan, which is part of the Industrial Solutions segment, is a pellet-based extrusion platform that addresses customer applications requiring large build volumes, superior performance, and improved productivity at significantly lower cost. We believe the acquisition of Titan will open up new markets in the Industrial Solutions segment. The acquisition’s near-term impact on the Company's results of operations and cash flows has been dilutive.

Saudi Arabian Industrial Investments Company

In March 2022, the Saudi Arabian Industrial Investments Company (“Dussur”) and 3D Systems signed an agreement to form a joint venture intended to expand the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The joint venture is to enable the development of Saudi Arabia's domestic additive manufacturing production capabilities, consistent with the Kingdom’s ‘Vision 2030,’ which is focused on diversification of the economy and long-term sustainability. Upon entering the agreement with Dussur, 3D Systems committed to an initial investment in the joint venture of approximately $6.5 million, of which $3.4 million had been deposited into an escrow account as of December 31, 2022 and, accordingly, was reported as restricted cash within other assets on the December 31, 2022 balance sheet. In February 2023, the Company became a shareholder in the joint venture and owns 49% of the joint venture's common stock. During April 2023, the $3.4 million held in escrow, as well as the additional amount of approximately $3.1 million owed to the joint venture, was deposited into a bank account of the joint venture for use in its operations. Additional future investments are contingent upon the achievement of certain milestones by the joint venture. The impact of this investment on the Company’s future financial position and cash flows is expected to be limited to cash outflow(s) related to future contingent investments, if required. The Company accounts for the joint venture under the equity method of accounting, which requires the Company to recognize its proportionate share of the joint venture's reported net income or loss. Due to the timing of when the joint venture's reported financial information is expected to be available, the Company records amounts required to be recognized pursuant to the equity method of accounting on a one quarter lag.

Enhatch Inc.

In March 2022, we made a $10.0 million investment for an approximate 26.6% ownership interest in Enhatch Inc. (“Enhatch”), the developer of the Intelligent Surgery Ecosystem. We simultaneously entered into a collaboration and supply agreement with Enhatch. We also obtained warrants to purchase additional shares of Enhatch and the right to purchase, in the future, the remaining shares of Enhatch that 3D Systems does not own, if certain revenue targets are achieved. Enhatch's Intelligent Surgery Ecosystem provides technologies which streamline and scale the design and delivery of patient-specific medical devices by automating the process. Incorporating these capabilities into 3D Systems’ workflow for patient-specific solutions, which includes advanced software, expert treatment planning services, custom implants, instrumentation design, and industry-leading production processes, will help more efficiently meet the growing demand for personalized medical devices.

Volumetric Biotechnologies, Inc.

On December 1, 2021, we acquired Volumetric Biotechnologies, Inc. (“Volumetric”) for $40.2 million. Additional payments of up to $355.0 million are possible upon (1) the attainment of seven non-financial milestones, each of which is measured individually and requires achievement prior to either December 31, 2030 or December 31, 2035, and (2) the continued employment of certain key individuals from Volumetric. Volumetric’s mission is to develop the ability to manufacture human organs using bioprinting methods and the underlying technologies required to create these highly complex biological structures. With this acquisition, we expanded our capabilities and capacity in 3D printing related to bio-printing and regenerative medicine. Combining 3D Systems' regenerative medicine group with Volumetric’s highly complementary skill sets of biological expertise and cellular engineering is expected to accelerate our core regenerative medicine strategies, which include the bio-printing of human organs, additional non-organ applications and bio-printing technologies for research labs. The acquisition’s near-term impact on the Company's results of operations and cash flows has been dilutive. Volumetric's operating results are reported in the Healthcare Solutions segment.

Oqton, Inc.

On November 1, 2021, we acquired Oqton, Inc. ("Oqton") for $187.8 million. Oqton is a software company that creates an intelligent, cloud-based MOS ("manufacturing operations system") platform tailored for flexible production environments that increasingly utilize a range of advanced manufacturing and automation technologies, including additive manufacturing solutions, in their production workflows. The cloud-based solution leverages the Industrial Internet of Things, artificial intelligence, and machine learning technologies to deliver a solution for customers to automate their digital manufacturing workflows, scale their operations and enhance their competitive position.

Since being acquired, Oqton’s impact on the consolidated Company’s financial position, results of operations and cash flows, as well as the reported results of the Industrial Solutions segment, has been dilutive. As such, the Company has been evaluating strategic alternatives for Oqton’s cloud-based MOS platform and, during the quarter ended September 30, 2023, the Company concluded that it is more likely than not that it will either sell or dispose of Oqton, which represents a discrete asset group within the Industrial Solutions segment and reporting unit. Based on this conclusion, the long-term cash flow forecast for Oqton was revised. The revised long-term cash flow forecast indicated that the carrying amount of the Oqton long-lived assets, consisting of recognized product technology and trade name intangible assets, may not be recoverable. Accordingly, the carrying value of these assets was tested for impairment. As a result of the sum of the present value of the estimated future cash flows expected to result from the use and eventual disposition of the asset group being less than the carrying value of the asset group, during the quarter ended September 30, 2023, the Company recognized $13.6 million of impairment charges related to the long-lived assets included in the asset group.

Investing in Regenerative Medicine

We continue to expand our focus and investments in the application of additive manufacturing for regenerative medicine. Currently, our efforts in the area of regenerative medicine consist mainly of pre-commercial research and development (“R&D”) and involve three strategies.

The first strategy is the use of additive manufacturing for human organ transplantation. Each year, end-stage organ failure kills millions of people. However, the supply of donated organs is insufficient to meet the needs of patients seeking transplantation. We have made significant progress in our organ printing development program, which we are conducting with a key strategic partner. This program was first established in 2017 and combines our legacy 3D printing expertise and our new capabilities in human tissue engineering from our acquisition of Volumetric in 2021 with the regenerative medicine and biotechnology expertise of our partner. To date, our program has focused on developing the capability to print scaffolds for human lungs, kidneys and livers, with a long-term goal of allowing patients with end-stage disease to receive transplants which will enable them to enjoy long and active lives.

Our second strategy involves utilizing our bio-printing technology to manufacture non-organ human tissue scaffolds for use in transplantation and surgical reconstruction applications. We believe that continued progress in this area could result in significantly improved health outcomes for patients, as well as open up attractive new growth markets and therapeutic applications for 3D printed, vascularized soft-tissue scaffolds.

Our third regenerative medicine strategy seeks to utilize our bio-printing capabilities to design and manufacture 3D-printed vascularized “organs-on-chips” for use in drug development by pharmaceutical industry customers through our wholly-owned biotech company, Systemic Bio. Currently, drug development is an expensive and time-consuming process, and many drug therapies that appear promising during pre-clinical trials fail during human clinical trials. We believe that “organs-on-chips” can accelerate the drug development process and reduce the cost of pre-clinical drug testing, as well as reduce the pharmaceutical industry’s reliance on animal testing. Systemic Bio combines 3D Systems’ legacy expertise in high-resolution 3D printing with advanced capabilities in bioprinting and biomaterials to design and market 3D-printed, vascularized “organs-on-chips” for sale to pharmaceutical industry customers. In the first quarter of 2023, we signed our first contract with a top pharmaceutical company.

Background

We earn revenue from the sale of products and services through our Healthcare Solutions and Industrial Solutions segments. The product categories include 3D printers and corresponding materials, digitizers, software licenses, 3D scanners and haptic devices. The majority of materials used in our 3D printers are proprietary. The services categories include maintenance contracts and services on 3D printers, software maintenance, software as a service subscriptions and healthcare solutions services.

Given the relatively high price of certain 3D printers and a corresponding lengthy selling cycle, as well as relatively low unit volume of the higher-priced printers in any particular period, a shift in the timing and concentration of orders and shipments from one period to another can materially affect reported revenue in any given period.

In addition to changes in sales volumes, there are two other primary drivers of changes in revenue from one period to another: (1) the combined effect of changes in product mix and average selling prices and (2) the impact of fluctuations in foreign currencies. As used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, the price and mix effects relate to changes in revenue that are not able to be specifically related to changes in unit volume or foreign exchange.

How We Assess the Performance of Our Business

We manage operations through the two business segments described above. In addition to our consolidated GAAP financial measures, we review Adjusted EBITDA.

We believe Adjusted EBITDA is a helpful supplemental measure to assist us and investors in evaluating our operating results, as Adjusted EBITDA excludes certain items for which the fluctuation from period to period does not necessarily correspond to changes in the operations of our business. Adjusted EBITDA represents net income (loss), plus income tax (provision) benefit, interest and other income (expense), net, stock-based compensation expense, amortization of intangible assets, depreciation expense, and certain other non-GAAP adjustments. We believe that the adjustments applied in presenting Adjusted EBITDA are appropriate to provide additional information to investors about (1) our operating and financial performance without the effect of certain material non-cash items and (2) non-recurring items that we do not expect to continue at the same level in the future.

Management and our Board of Directors regularly use Adjusted EBITDA in evaluating our operating and financial performance and in establishing discretionary annual compensation. This measure is provided in addition to, and should not be considered to be a substitute for, or superior to, comparable measures determined in accordance with GAAP. In addition, we believe that Adjusted EBITDA is frequently used by investors and other interested parties in the evaluation of other issuers, many of which also present Adjusted EBITDA when reporting their results in an effort to augment investors' understanding of their operating and financial results; however, similarly titled measures provided by other issuers may not be calculated in the same manner and/or using the same adjustments.

Adjusted EBITDA should not be considered as an alternative to net income (loss) or any other performance measure derived in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool, and you should not consider such measure either in isolation or as a substitute for analyzing our results as reported under GAAP.

For further information regarding Adjusted EBITDA, see “Reconciliation of non-GAAP Measures” below.

Consolidated Financial Results for the Three and Nine Months Ended September 30, 2023 and 2022

(in thousands)

Revenue: Three Months Ended September 30, 2023 September 30, 2022 Nine Months Ended September 30, 2023 September 30, 2022
Products $80,415 $96,337 $253,968 $300,662
Services 43,376 35,916 119,253 104,637
Total revenue 123,791 132,253 373,221 405,299
Cost of sales:
Products 47,427 58,042 153,442 181,845
Services 21,014 21,541 67,315 63,851
Total cost of sales 68,441 79,583 220,757 245,696
Gross profit 55,350 52,670 152,464 159,603
Operating expenses:
Selling, general and administrative 33,355 65,579 150,623 185,398
Research and development 21,982 20,796 66,953 63,180
Impairment of intangible assets 13,597 — 13,597
Total operating expenses 68,934 86,375 231,173 248,578
Loss from operations (13,584) (33,705) (78,709) (88,975)
Interest and other income (expense), net 2,602 (3,502) 9,691 (5,456)
(Loss) income before income taxes (10,982) (37,207) (69,018) (94,431)
(Provision) benefit for income taxes (174) (338) (404) (2,911)
(Loss) on equity method investment, net of income taxes (605) — (747) —
Net (loss) income before redeemable non-controlling interest (11,761) (37,545) (70,169) (97,342)
Less: net (loss) income attributable to redeemable non-controlling interest (57) (147) (149) (184)
Net (loss) income attributable to 3D Systems Corporation $(11,704) $(37,398) $(70,020) $(97,158)
Other Financial Data:
Adjusted EBITDA $4,726 $(321) $(12,266) $(977)

40

Operating Results for the Three Months Ended September 30, 2023 Compared to the Three Months Ended September 30, 2022

Consolidated revenue

The following table sets forth changes in our products and services revenue for the three months ended September 30, 2023 and 2022.

(Dollars in thousands)

Products Services Total
Revenue — Three months ended September 30, 2022 $96,337 72.8% $35,916 27.2% $132,253 100.0%
Change in revenue:
Volume (19,290) (20.0)% 6,653 18.5% (12,637) (9.6)%
Price/mix 1,351 1.4% — —% 1,351 1.0%
Foreign currency translation 2,017 2.1% 807 2.2% 2,824 2.1%
Net change (15,922) (16.5)% 7,460 20.7% (8,462) (6.4)%
Revenue — Three months ended September 30, 2023 $80,415 65.0% $43,376 35.0% $123,791 100.0%

Products revenue

For the three months ended September 30, 2023, products revenue decreased by $15.9 million, or 16.5%, as compared to the three months ended September 30, 2022. Lower sales volume resulted in a $19.3 million, or 20.0%, decrease in reported product revenue relative to the prior year period, of which $19.0 million of such decrease is attributable to our Healthcare Solutions segment. The lower sales volume within our Healthcare Solutions segment was primarily due to lower sales to the dental market, as the demand for related elective dental procedures that our products support has been impacted by current economic conditions. Product sales volume in our Healthcare Solutions segment also decreased due to lower printer sales into the medical devices market. As shown in the table, a favorable impact of price/mix, primarily related to our Healthcare Solutions segment, and a favorable impact of foreign currency translation, related to both the Healthcare Solutions and Industrial Solutions segments, partially offset the significant decrease in revenue attributable to our Healthcare Solutions segment's lower sales volume.

Services revenue

For the three months ended September 30, 2023, services revenue increased by $7.5 million, or 20.7%, as compared to the three months ended September 30, 2022. Higher sales volume resulted in a $6.6 million, or 18.5%, increase in reported services revenue relative to the prior year period, of which $4.4 million and $2.2 million of the increase relates to our Healthcare Solutions segment and our Industrial Solutions segment, respectively. Services revenue recognized by our Healthcare Solutions segment increased primarily due to incremental variable consideration (revenue) being deemed probable of being earned under a regenerative medicine collaboration and licensing agreement that was amended during the three months ended September 30, 2023. In connection with the amendment to this collaboration and licensing agreement, the Company concluded that three additional milestone-based payments included in the contract, totaling $6.5 million in the aggregate, became probable of being earned, for which an aggregate of $4.5 million of revenue was recognized during the three months ended September 30, 2023. Revenue related to the collaboration and licensing agreement is recognized over time and, accordingly, the remaining $2.0 million of revenue attributable to the three additional milestone payments is expected to be recognized over the remaining duration of the contract.

The $2.2 million increase in the services revenue attributable to our Industrial Solutions segment relates to increases in revenue generated from hardware services, parts manufacturing services, and software maintenance.

Total revenue

For the three months ended September 30, 2023, total revenue decreased by $8.5 million, or 6.4%, as compared to the three months ended September 30, 2022, as the decrease in our products revenue exceeded the increase in our services revenue, as described above.

Consolidated gross profit

(Dollars in thousands)

Three Months Ended September 30, 2023 Gross Profit Gross Profit Margin September 30, 2022 Gross Profit Gross Profit Margin Change in Gross Profit $% Change in Gross Profit Margin Percentage Points%
Products $32,988 41.0% $38,295 39.8% $(5,307) (13.9)% 1.2 3.0%
Services 22,362 51.6% 14,375 40.0% 7,987 55.6% 11.6 29.0%
Total $55,350 44.7% $52,670 39.8% $2,680 5.1% 4.9 12.3%

Products gross profit and gross profit margin

For the three months ended September 30, 2023, gross profit from products sales decreased by $5.3 million, or 13.9%, as compared to the three months ended September 30, 2022. Gross profit decreased $9.0 million due to lower sales volumes and the resulting decrease in product revenue, which decrease was partially offset by a favorable impact of sales price/mix. Gross profit margin increased due to the favorable impact of sales price/mix.

Services gross profit and gross profit margin

For the three months ended September 30, 2023, gross profit from services sales increased $8.0 million, or 55.6%, as compared to the three months ended September 30, 2022. The increase in gross profit from services sales was driven by the $6.6 million, or 18.5%, increase in services revenue attributable to higher sales volume, favorable impacts of cost reductions due to reduced headcount, and a favorable impact of foreign currency exchange. The increase in services revenue includes the $4.5 million of incremental variable consideration revenue recognized by our Healthcare Solutions segment upon concluding that additional milestone-based payments included in a collaboration and licensing revenue agreement are probable of being earned. As there were no direct costs (e.g., costs of goods sold) associated with this incremental collaboration and licensing revenue, the entire $4.5 million contributed to an increase in our reported gross profit, as well as to a 5.5% increase and 2.1% increase in our services gross profit margin and consolidated gross profit margin, respectively. In addition, a $2.2 million increase in services revenue attributable to our Industrial Solutions segment contributed to a $1.5 million increase in our reported gross profit.

Consolidated selling, general and administrative expense

Selling, general and administrative ("SG&A") expense for the three months ended September 30, 2023 decreased $32.2 million, or 49.1%, to $33.4 million, as compared to $65.6 million for the three months ended September 30, 2022. The primary drivers of the $32.2 million decrease in SG&A expense reported for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022, are as follows:

Primary drivers (in thousands) Increase / (Decrease)
Volumetric earnout $(24,260)
Legal and contingency costs (4,819)
Compensation and benefits (inclusive of stock-based compensation) (4,391)
Consulting and outside services 1,289
Severance 674
Other (717)
Total change $(32,224)

42

Volumetric earnout expense decreased $24.3 million as the Company reversed $20.3 million of previously recognized earnout expense during the three months ended September 30, 2023, as compared to recognizing $4.0 million of earnout expense during the three months ended September 30, 2022. Prior to the current quarter ended September 30, 2023, the Company was accruing for a potential earnout payment of $65 million (compensation expense) based upon the expected achievement of a non-financial milestone outlined in the Volumetric acquisition agreement. Expense related to the potential earnout payment was being recognized on a straight-line basis through the anticipated date of achievement of the related milestone. However, as of the current quarter ended September 30, 2023, the Company has concluded that this non-financial milestone is no longer probable of being achieved due to a reduction in the budgeted funding for the related research and development efforts, resulting in the reversal of all previously recognized compensation expense. Refer to Note 12 and our discussion of "Critical Accounting Estimates" for additional details.

The decrease in legal and contingency costs for the three months ended September 30, 2023 is primarily due to the Company's accrual of approximately $9.7 million in estimated costs related to the government compliance matters discussed in Note 18 during the quarter ended September 30, 2022. Those government compliance matters were ultimately settled during the quarter ended March 31, 2023. No events that would require the recognition of a similar material legal contingency accrual occurred during the three months ended September 30, 2023. An increase in other legal fees incurred during the three months ended September 30, 2023 partially offset the impact of not recording similar legal and contingency costs during the quarter ended September 30, 2023.

The decrease in compensation and benefit costs for the three months ended September 30, 2023 is primarily attributable to $5.2 million of lower bonus and stock-based compensation expense recognized during the quarter ended September 30, 2023, partially offset by an increase in ordinary salaries and wages and benefit costs, as compared to the three months ended September 30, 2022. Lower bonus expense is primarily attributable to the reversal of previously accrued performance-based bonus expense during the quarter ended September 30, 2023. Lower stock-based compensation expense is primarily attributable to the reversal of $1.2 million of expense attributable to performance-based restricted stock units during the quarter ended September 30, 2023, for which the performance condition required to be achieved is identical to the Volumetric non-financial milestone that is no longer deemed probable of being met due to the reduction in the budgeted funding for the related research and development efforts. Refer to Note 12 and our discussion of "Critical Accounting Estimates" for additional details.

The increase in consulting and outside services for the three months ended September 30, 2023 reflects an increase in the use of third-party service providers to support various functions within the Company, including certain internal transformation efforts.

The increase in severance costs for the three months ended September 30, 2023 reflects costs incurred in connection with the Company's continued reduction in headcount in its corporate and business support functions, as part of its restructuring plan announced during the quarter ended June 30, 2023. The reduction in headcount reflects the Company's commitment to rationalizing its operations and improving its operating efficiency.

Consolidated research and development expense

Research and development ("R&D") expense for the three months ended September 30, 2023 increased $1.2 million, or 5.7%, to $22.0 million, as compared to $20.8 million for the three months ended September 30, 2022. R&D expense increased $2.1 million related to our regenerative medicine research activities primarily attributable to our wholly-owned subsidiary, Systemic Bio, and $0.6 million due to the Company’s acquisitions of dp polar in October of 2022 and Wematter in July of 2023. While the Company's R&D expense reported for the three months ended September 30, 2023 includes amounts incurred as part of dp polar's and Wematter's operating activities, neither of these entities had been acquired as of September 30, 2022 and, accordingly, their operating results were not part of the Company's reported results for the three months then ended. Offsetting the increase in R&D costs attributable to regenerative medicine research activities and recent acquisitions is a reduction in corporate R&D costs.

Impairment of intangible assets

During the quarter ended September 30, 2023, the Company concluded that it is more likely than not that it will sell or otherwise dispose of Oqton MOS, a business which the Company acquired in 2021. Based upon the Company's expectation to sell or otherwise dispose of Oqton MOS, the Company assessed the carrying value of Oqton MOS's long-lived assets, a discrete asset group consisting primarily of product technology and trade name intangible assets initially recorded when Oqton MOS was acquired, for both recoverability and impairment. The Company's assessment resulted in the recognition of impairment charges totaling $13.6 million related to the acquired technology and trade names included in the Oqton MOS asset group during the three months ended September 30, 2023.

Consolidated operating loss

Our operating loss was $13.6 million for the three months ended September 30, 2023, as compared to $33.7 million for the three months ended September 30, 2022. The decrease in our reported operating loss for the quarter ended September 30, 2023 was due to the $2.7 million increase in our gross profit and $32.2 million decrease in SG&A costs reported for the quarter ended September 30, 2023, as compared to the quarter ended September 30, 2022, which more than offset (1) the $1.2 million period-over-period increase in R&D costs and (2) $13.6 million impairment charge recorded during the quarter ended September 30, 2023. Refer to the discussion above for additional details regarding the variances in the amounts reported for each of the aforementioned financial statement line items for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022, as well as the factors contributing to those variances.

Operating Results for the Nine Months Ended September 30, 2023 Compared to the Nine Months Ended September 30, 2022

Consolidated revenue

The following table sets forth changes in our products and services revenue for the nine months ended September 30, 2023 and 2022.

(Dollars in thousands)

Products Services Total
Revenue — nine months ended September 30, 2022 $300,662 74.2% $104,637 25.8% $405,299 100.0%
Change in revenue:
Volume (52,257) (17.4)% 14,522 13.9% (37,735) (9.3)%
Price/mix 5,519 1.8% — —% 5,519 1.4%
Foreign currency translation 44 —% 94 0.1% 138 —%
Net change (46,694) (15.6)% 14,616 14.0% (32,078) (7.9)%
Revenue — nine months ended September 30, 2023 $253,968 68.0% $119,253 32.0% $373,221 100.0%

Products revenue

For the nine months ended September 30, 2023, products revenue decreased by $46.7 million, or 15.6%, as compared to the nine months ended September 30, 2022. Lower sales volume resulted in a $52.3 million, or 17.4%, decrease in reported product revenue relative to the prior year period, of which $51.8 million of such decrease is attributable to our Healthcare Solutions segment. The lower product sales volume within our Healthcare Solutions segment was primarily due to lower sales to the dental market, as the demand for elective dental procedures that our products support has been impacted by current economic conditions. Product sales volume in our Healthcare Solutions segment also decreased due to lower printer sales into the medical devices market. As shown in the table, favorable impacts of price/mix, also primarily related to our Healthcare Solutions segment, partially offset the significant decrease in revenue attributable to lower sales volume within the Healthcare Solutions segment.

Services revenue

For the nine months ended September 30, 2023, services revenue increased by $14.6 million, or 14.0%, as compared to the nine months ended September 30, 2022. Higher sales volume resulted in a $14.5 million, or 13.9%, increase in reported services revenue relative to the prior year period, of which $8.6 million and $5.9 million of such increase is attributable to our Healthcare Solutions segment and our Industrial Solutions segment, respectively. The largest contributor to the increase in the services revenue realized by our Healthcare Solutions segment was incremental variable consideration (revenue) being deemed probable of being earned under a regenerative medicine collaboration and licensing agreement that was amended during the three months ended September 30, 2023. In connection with the amendment to this collaboration and licensing agreement, the Company concluded that three additional milestone-based payments included in the contract, totaling $6.5 million in the aggregate, became probable of being earned, for which an aggregate of $4.5 million of revenue was recognized during the three months ended September 30, 2023. Revenue related to the collaboration and licensing agreement is recognized over time and, accordingly, the remaining $2.0 million of revenue attributable to the three additional milestone payments is expected to be recognized over the remaining duration of the contract. In addition, the increase in services sales volume within our Healthcare Solutions segment relates to personalized healthcare solutions and advanced manufacturing services.

The increase in the services sales volume realized by our Industrial Solutions segment primarily relates to hardware services and parts manufacturing.

Total revenue

For the nine months ended September 30, 2023, total revenue decreased by $32.1 million, or 7.9%, compared to the nine months ended September 30, 2022, as the decrease in our products revenue exceeded the increase in our services revenue, as described above.

Consolidated gross profit

(Dollars in thousands)

Nine Months Ended September 30, 2023 Gross Profit Gross Profit Margin September 30, 2022 Gross Profit Gross Profit Margin Change in Gross Profit $% Change in Gross Profit Margin Percentage Points%
Products $100,526 39.6% $118,817 39.5% $(18,291) (15.4)% 0.1 0.3%
Services 51,938 43.6% 40,786 39.0% 11,152 27.3% 4.6 11.8%
Total $152,464 40.9% $159,603 39.4% $(7,139) (4.5)% 1.5 3.8%

Products gross profit and gross profit margin

For the nine months ended September 30, 2023, gross profit from products sales decreased by $18.3 million, or 15.4%, as compared to the nine months ended September 30, 2022. The decrease in gross profit from products sales is primarily due to the corresponding 15.6% decrease in products sales revenue.

Services gross profit and gross profit margin

For the nine months ended September 30, 2023, gross profit from services sales increased by $11.2 million, or 27.3%, as compared to the nine months ended September 30, 2022. The increase in gross profit from services sales was primarily driven by the $14.5 million, or 13.9%, increase in services revenue attributable to higher sales volume. The increase in services revenue includes the $4.5 million of incremental variable consideration revenue recognized by our Healthcare Solutions segment during the three months ended September 30, 2023, upon concluding that additional milestone-based payments included in a collaboration and licensing revenue agreement are probable of being earned. As there were no direct costs (e.g., costs of goods sold) associated with this incremental collaboration and licensing revenue, the entire $4.5 million contributed to an increase in our reported gross profit, as well as to a 2.2% increase and 0.7% increase in our services gross profit margin and consolidated gross profit margin, respectively, for the nine months ended September 30, 2023. In addition, a general increase in services revenue attributable to both our Industrial Solutions and Healthcare Solutions segments contributed to an increase in our reported services gross profit due to the fixed nature of the costs (e.g., salaries) incurred to provide certain of our services.

Consolidated selling, general and administrative expense

SG&A expense for the nine months ended September 30, 2023 decreased $34.8 million, or 18.8%, to $150.6 million, as compared to $185.4 million for the nine months ended September 30, 2022. The primary drivers of the $34.8 million decrease in SG&A expense reported for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022 — inclusive of the impacts of the acquisitions described above — are as follows:

Primary drivers (in thousands) Increase / (Decrease)
Volumetric earnout $(29,218)
Legal and contingency costs (13,218)
Consulting and outside services 4,079
Severance 3,484
Other 98
Total change $(34,775)

45

Volumetric earnout expense decreased $29.2 million as the Company reversed $17.3 million of previously recognized earnout expense during the nine months ended September 30, 2023, as compared to recognizing $11.9 million of earnout expense during the nine months ended September 30, 2022. The reversal of $17.3 million of expense for the nine months ended September 30, 2023 reflects the reversal of $20.3 million of expense during the current quarter, net of $3.0 million of earnout expense recognized through June 30, 2023. Prior to the current quarter ended September 30, 2023, the Company was accruing for a potential earnout payment of $65 million (compensation expense) based upon the expected achievement of a non-financial milestone outlined in the Volumetric acquisition agreement. Expense related to the potential earnout payment was being recognized on a straight-line basis through the anticipated date of achievement of the related milestone. However, as of the current quarter ended September 30, 2023, the Company has concluded that this non-financial milestone is no longer probable of being achieved due to a reduction in the budgeted funding for the related R&D efforts, resulting in the reversal of all previously recognized compensation expense. Refer to Note 12 and our discussion of "Critical Accounting Estimates" for additional details.

The decrease in legal and contingency costs for the nine months ended September 30, 2023 is primarily due to the Company's accrual of approximately $18.1 million in estimated costs related to the government compliance matters discussed in Note 18 during the nine months ended September 30, 2022. Based upon subsequent settlement discussions, this accrual amount was adjusted in the fourth quarter of fiscal year 2022, and the government compliance matters were ultimately settled during the quarter ended March 31, 2023 without a need for further adjustment to the accrual during such period. No events that would require the recognition of a similar material legal contingency accrual occurred during the nine months ended September 30, 2023. An increase in other legal fees incurred during the nine months ended September 30, 2023 partially offset the impact of not recording similar legal contingency costs during the nine-month period.

The increase in consulting and outside services costs for the nine months ended September 30, 2023 reflects an increase in the use of third-party service providers to support various functions within the Company, including certain internal transformation efforts, as well as an increase in audit and accounting fees.

The increase in severance costs for the nine months ended September 30, 2023 reflects costs incurred in connection with the Company's reduction in headcount in its corporate and business support functions, as part of its restructuring plan announced during the quarter ended June 30, 2023, as well as severance costs incurred during the quarter ended March 31, 2023 prior to the announcement of the formal restructuring plan. The reduction in headcount pursuant to the restructuring plan reflects the Company's commitment to rationalizing its operations and improving its operating efficiency.

Consolidated research and development expense

R&D expense for the nine months ended September 30, 2023 increased $3.8 million, or 6.0%,to $67.0 million as compared to $63.2 million for the nine months ended September 30, 2022. R&D expense increased $2.5 million due to the timing of the Company’s acquisitions of Titan, Kumovis, and dp polar during fiscal year 2022, as well as the acquisition of Wematter in July of 2023. As Titan and Kumovis were not acquired by the Company until April 1, 2022, their operating activities are only reflected in the Company's reported results for six months of the nine-month period ended September 30, 2022. As dp polar and Wematter were acquired by the Company after September 30, 2022, their operations were not part of the Company's reported results for any portion of the nine months then ended.

In addition to the impact of recent acquisitions, R&D expense increased $4.2 million related to our regenerative medicine research activities primarily attributable to our wholly-owned subsidiary, Systemic Bio. Offsetting the increase in R&D costs attributable to regenerative medicine research activities and recent acquisitions is a reduction in corporate R&D costs.

Impairment of intangible assets

During the quarter ended September 30, 2023, the Company concluded that it is more likely than not that it will sell or otherwise dispose of Oqton MOS, a business which the Company acquired in 2021. Based upon the Company's expectation to sell or otherwise dispose of Oqton MOS, the Company assessed the carrying value of Oqton MOS's long-lived assets, a discrete asset group consisting primarily of product technology and trade name intangible assets initially recorded when Oqton MOS was acquired, for both recoverability and impairment. The Company's assessment resulted in the recognition of impairment charges totaling $13.6 million related to the acquired technology and trade names included in the Oqton MOS asset group during the nine months ended September 30, 2023.

Consolidated operating loss

Our operating loss for the nine months ended September 30, 2023 was $78.7 million, as compared to $89.0 million for the nine months ended September 30, 2022. The decrease in our reported operating loss for the nine months ended September 30, 2023 was primarily due to our $34.8 million decrease in SG&A expense for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, which more than offet the impact of (1) our lower reported revenue and the corresponding decrease in our gross profit for the nine months ended September 30, 2023, (2) the $3.8 million period-over-period increase in our R&D expense, and (3) the $13.6 million impairment charge recognized during the period. Refer to the discussion above for additional details regarding the variances in the amounts reported for each of the financial statement line items that comprise our reported operating loss for the nine months ended September 30, 2023 and September 30, 2022.

Non-Operating Income (Loss) for the Three and Nine Months Ended September 30, 2023 compared to the Three and Nine Months Ended September 30, 2022

Interest and other income (expense), net

The following table sets forth the components of interest and other income (expense), net for the three and nine months ended September 30, 2023 and 2022.

(in thousands)

Interest and other income (expense), net Three Months Ended September 30, 2023 September 30, 2022 Nine Months Ended September 30, 2023 September 30, 2022
Foreign exchange (loss), net $(2,202) $(764) $(3,847) $(4,193)
Interest income, net 4,909 2,029 13,118 4,019
Other (expense) income, net (105) (4,767) 420 (5,282)
Total interest and other income (expense), net $2,602 $(3,502) $9,691 $(5,456)

For the three and nine months ended September 30, 2023, interest income, net increased as compared to the three and nine months ended September 30, 2022 due to higher interest income earned on cash and cash equivalents resulting from increased interest rates during the three and nine months ended September 30, 2023.

For the three and nine months ended September 30, 2023, other expense decreased primarily due to the $2.8 million impairment loss recorded with respect to the Company's investment in Enhatch during the three months ended September 30, 2022. There were no similar impairments recognized with respect to the Company's investments during the three and nine months ended September 30, 2023.

Net (loss) income

The following table sets forth our net (loss) income for the three and nine months ended September 30, 2023, and 2022.

(in thousands, except per share amounts)

Three Months Ended September 30, 2023 September 30, 2022 Nine Months Ended September 30, 2023 September 30, 2022
(Loss) income before income taxes $(10,982) $(37,207) $(69,018) $(94,431)
(Provision) benefit for income taxes (174) (338) (404) (2,911)
(Loss) on equity method investment, net of income taxes (605) — (747) —
Net (loss) income before redeemable non-controlling interest (11,761) (37,545) (70,169) (97,342)
Less: net (loss) income attributable to redeemable non-controlling interest (57) (147) (149) (184)
Net (loss) income attributable to 3D Systems Corporation $(11,704) $(37,398) $(70,020) $(97,158)
Net (loss) income per common share:
Basic $(0.09) $(0.30) $(0.54) $(0.77)
Diluted $(0.09) $(0.30) $(0.54) $(0.77)

Our tax provision for the three and nine months ended September 30, 2023 was $0.2 million and $0.4 million, respectively, as compared to $0.3 million and $2.9 million for the three and nine months ended September 30, 2022, respectively. The Company's effective tax rates for the three and nine months ended September 30, 2023 and 2022 were significantly below the U.S. and foreign jurisdictions' statutory tax rates due to (1) the Company's reported losses and (2) the maintenance of a valuation allowance against deferred tax assets generated by such losses based upon the Company's conclusion that it is more likely than not that its deferred tax assets will not be realized in various tax jurisdictions.

The decrease in the net loss attributable to 3D Systems for the three months ended September 30, 2023, as compared to the net loss attributable to 3D Systems for the three months ended September 30, 2022, was primarily driven by the period-over period decrease in the Company's consolidated operating loss (as described above) and the increase in interest and other income (expense), net for the quarter ended September 30, 2023, partially offset by the loss on equity method investment. As of September 30, 2022, the Company did not have an investment accounted for under the equity method of accounting.

The decrease in the net loss attributable to 3D Systems for the nine months ended September 30, 2023, as compared to the net loss attributable to 3D Systems for the nine months ended September 30, 2022, was primarily due to the period-over-period decrease in the Company's consolidated operating loss (as described above), the increase in interest and other income (expense), net for the nine months ended September 30, 2023, and the lower tax provision for the nine months ended September 30, 2023, partially offset by the loss on equity method investment. As of September 30, 2022, the Company did not have an investment accounted for under the equity method of accounting.

Non-GAAP Earnings

Adjusted EBITDA

Our Adjusted EBITDA increased from negative $0.3 million for the three months ended September 30, 2022 to positive $4.7 million for the three months ended September 30, 2023. This increase of $5.0 million in our reported adjusted EBITDA was driven by a $20.1 million decrease in our reported operating loss for the three months ended September 30, 2023, adjusted for the period-over-period changes in certain operating costs that are included in the determination of our GAAP operating loss, but are excluded from our calculation of Adjusted EBITDA. As shown in the reconciliation of our reported Net Loss to Adjusted EBITDA (below), GAAP costs for which period-over-period variances materially impacted our reported operating loss for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022, but are excluded from the calculation of Adjusted EBITDA for each of those respective periods, include amortization expense, stock-based compensation expense, acquisition and divestiture-related expense, litigation costs, restructuring expense, and impairment losses.

Our Adjusted EBITDA decreased from negative $1.0 million for the nine months ended September 30, 2022 to negative $12.3 million for the nine months ended September 30, 2023, despite a $10.3 million decrease in our reported operating loss for the nine months ended September 30, 2023. The decrease in our reported operating loss for the nine months ended September 30, 2023 did not result in a corresponding improvement to our Adjusted EBITDA as certain operating expenses that are included in the determination of our GAAP operating loss, and for which there were material period-over-period variances in the amounts reported, are excluded from our calculation of Adjusted EBITDA. As shown in the reconciliation of our reported Net Loss to Adjusted EBITDA (below), GAAP costs for which period-over-period variances materially impacted our reported operating loss for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, but are excluded from the calculation of Adjusted EBITDA for each of those respective periods, include amortization expense, stock-based compensation expense, acquisition and divestiture-related expense, litigation costs, restructuring expense, and impairment losses.

Reconciliation of Non-GAAP Measures

The table that follows provides a reconciliation of the Company's reported Net Loss to Adjusted EBITDA. Refer to the discussion of "How We Assess the Performance of Our Business" for additional information regarding Adjusted EBITDA, and why management believes this measure provides useful information regarding the Company's results of operations.

(in thousands)

Three Months Ended September 30, 2023 September 30, 2022 Nine Months Ended September 30, 2023 September 30, 2022
Net loss attributable to 3D Systems Corporation $(11,704) $(37,398) $(70,020) $(97,158)
Interest (income) expense, net (4,909) (2,029) (13,118) (4,019)
Provision (benefit) for income taxes 174 338 404 2,911
Depreciation expense 5,084 5,142 15,690 15,992
Amortization expense 3,179 4,293 9,676 10,273
Stock-based compensation expense (3,142) 11,447 15,140 31,508
Acquisition and divestiture-related expense (4,055) 2,728 134 9,382
Legal expenses 2,145 9,707 4,880 20,467
Restructuring expense 1,504 67 6,712 376
Redeemable non-controlling interest (57) (147) (149) (184)
Loss on equity method investment 605 — 747 —
Asset impairment charges 13,595 2,909 14,211 2,885
Other non-operating (income) expense 2,307 2,622 3,427 6,590
Adjusted EBITDA $4,726 $(321) $(12,266) $(977)

49

Segment Financial Results for the Three and Nine Months Ended September 30, 2023 and 2022

Effective January 1, 2023, and for periods subsequent thereto, Adjusted EBITDA reflects the measure of profitability used by the Company’s chief operating decision maker (“CODM”) to evaluate the performance of the Company’s reportable segments. In addition, as of January 1, 2023, the Company's methodology for allocating certain costs between its segments was revised to more closely reflect changes in the Company's business and estimates of usage of shared resources by the Company's segments. Prior year amounts have been reclassified to conform with current year presentation.

Segment Results for the Three Months Ended September 30, 2023 Compared to the Three Months Ended September 30, 2022

The following table presents the revenue and Adjusted EBITDA amounts reported by each of our segments, as well as non-allocated corporate costs, for the three months ended September 30, 2023 and 2022:

(in thousands)

Revenue Three Months Ended September 30, 2023 September 30, 2022 Change Adjusted EBITDA Three Months Ended September 30, 2023 September 30, 2022 Change
Healthcare Solutions $52,429 $64,203 $(11,774) $13,869 $13,787 $82
Industrial Solutions 71,362 68,050 3,312 7,662 7,180 482
Corporate and Other — — — (16,805) (21,288) 4,483
Total Company $123,791 $132,253 $(8,462) $4,726 $(321) $5,047

Healthcare Solutions

Revenue

For the three months ended September 30, 2023, Healthcare Solutions revenue decreased $11.8 million, or 18.3%, as compared to the three months ended September 30, 2022. This decrease in segment revenue was primarily due to (1) a $13.3 million, or 39.1%, decrease in sales to the dental market, as the demand for related elective dental procedures that our products support has been impacted by current economic conditions, and (2) a $3.0 million, or 12%, decrease in sales to the medical devices market. The decrease in sales into the dental and medical devices markets was partially offset by the $4.5 million increase in variable consideration revenue recognized with respect to a regenerative medicine collaboration and licensing revenue agreement for which the Company concluded that additional milestone-based payments became probable of being earned upon amendment of the agreement during the quarter ended September 30, 2023.

Adjusted EBITDA

For the three months ended September 30, 2023, Adjusted EBITDA for our Healthcare Solutions segment was flat as compared to the three months ended September 30, 2022, despite lower reported revenue, as the decrease in segment EBITDA due to lower sales to the dental market was effectively offset by the $4.5 million increase in variable consideration revenue recognized with respect to a regenerative medicine collaboration and licensing revenue agreement for which the Company concluded that additional milestone-based payments became probable of being earned upon amendment of the agreement during the quarter ended September 30, 2023. The entire $4.5 million increase in recognized variable consideration revenue contributed to an increase in segment gross profit and Adjusted EBITDA.

Industrial Solutions

Revenue

For the three months ended September 30, 2023, Industrial Solutions revenue increased $3.3 million, or 4.9%, as compared to the three months ended September 30, 2022. The increase in segment revenue is primarily attributable to a $2.2 million increase in services revenue related to hardware services, parts manufacturing services, and software maintenance, as well as the favorable impact of foreign exchange rates.

Adjusted EBITDA

For the three months ended September 30, 2023, Adjusted EBITDA for our Industrial Solutions segment increased $0.5 million, or 6.7%, as compared to the three months ended September 30, 2022, which was primarily driven by a favorable impact of price/mix, partially offset by an unfavorable impact of the Company's recent acquisitions of dp polar and Wematter.

Corporate and Other

Adjusted EBITDA

For the three months ended September 30, 2023, Corporate and Other Adjusted EBITDA was negative $16.8 million, as compared to negative $21.3 million for the three months ended September 30, 2022. The improvement of $4.5 million was primarily driven by a $3.6 million decrease in unallocated corporate operating expense and a $0.6 million favorable impact of foreign exchange rates. The decrease in unallocated corporate operate expense for the three months ended September 30, 2023 primarily relates to lower legal costs, a larger reversal of annual bonus expense, and lower workforce expense within corporate functions.

Segment Results for the Nine Months Ended September 30, 2023 Compared to the Nine Months Ended September 30, 2022

The following table presents the revenue and Adjusted EBITDA amounts reported by each of our segments, as well as non-allocated corporate costs, for the nine months ended September 30, 2023 and 2022:

(in thousands)

Revenue Nine Months Ended September 30, 2023 September 30, 2022 Change Adjusted EBITDA Nine Months Ended September 30, 2023 September 30, 2022 Change
Healthcare Solutions $162,028 $200,294 $(38,266) $30,328 $45,705 $(15,377)
Industrial Solutions 211,193 205,005 6,188 16,828 16,473 355
Corporate and Other — — — (59,422) (63,155) 3,733
Total Company $373,221 $405,299 $(32,078) $(12,266) $(977) $(11,289)

Healthcare Solutions

Revenue

For the nine months ended September 30, 2023, Healthcare Solutions revenue decreased $38.3 million, or 19.1%, as compared to the nine months ended September 30, 2022. The decrease in segment revenue was primarily due to a $43.0 million, or 35.9%, decrease in sales to the dental market, as the demand for related elective dental procedures that our products support has been impacted by current economic conditions. The decrease in sales into the dental market was offset by the $4.5 million increase in variable consideration revenue recognized with respect to a regenerative medicine collaboration and licensing revenue agreement for which the Company concluded that additional milestone-based payments became probable of being earned upon amendment of the agreement during the quarter ended September 30, 2023.

Adjusted EBITDA

For the nine months ended September 30, 2023, Adjusted EBITDA for our Healthcare Solutions segment decreased $15.4 million, or 33.6%, as compared to the nine months ended September 30, 2022, which was primarily driven by the decrease in segment revenue related to lower sales to the dental market, partially offset by a favorable impact of pricing/mix.

Industrial Solutions

Revenue

For the nine months ended September 30, 2023, Industrial Solutions revenue increased $6.2 million, or 3.0%, as compared to the nine months ended September 30, 2022. The increase in segment revenue is primarily attributable to a $5.9 million increase in services revenue related to hardware services and parts manufacturing services.

Adjusted EBITDA

For the nine months ended September 30, 2023, Adjusted EBITDA for our Industrial Solutions segment increased $0.4 million, or 2.2%, as compared to the nine months ended September 30, 2022. The increase in segment Adjusted EBITDA is primarily reflective of the increase in services sales and favorable impacts of pricing/mix and foreign exchange rates, partially offset by a net negative impact of the Company's recent acquisitions of Titan, dp polar, and Wematter.

Corporate and Other

Adjusted EBITDA

For the nine months ended September 30, 2023, Corporate and Other Adjusted EBITDA was negative $59.4 million, as compared to negative $63.2 million for the nine months ended September 30, 2022. This improvement in Adjusted EBITDA was primarily driven by a $2.8 million decrease in unallocated corporate operating expense and a $0.9 million favorable impact of foreign exchange rates. The decrease in unallocated corporate operate expense for the nine months ended September 30, 2023 primarily relates to lower legal costs.

Liquidity and Capital Resources

The following table sets forth the Company's operating working capital at September 30, 2023 and December 31, 2022.

(Dollars in thousands)

September 30, 2023 December 31, 2022 Change $%
Cash and cash equivalents $445,554 $388,134 $57,420 14.8%
Short-term investments — 180,603 (180,603) (100.0)%
Accounts receivable, net 104,516 93,886 10,630 11.3%
Inventories 153,005 137,832 15,173 11.0%
703,075 800,455 (97,380) (12.2)%
Less:
Current lease liabilities 10,684 9,036 1,648 18.2%
Accounts payable 46,108 53,826 (7,718) (14.3)%
Accrued and other liabilities 43,575 55,571 (11,996) (21.6)%
100,367 118,433 (18,066) (15.3)%
Operating working capital $602,708 $682,022 $(79,314) (11.6)%

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. In doing so, we review and analyze our current cash on hand, the number of days our sales are outstanding, inventory turns, capital expenditure commitments and accounts payable turns. Our cash requirements, excluding acquisitions, primarily consist of funding working capital and capital expenditures.

At September 30, 2023, cash and cash equivalents and short-term investments totaled $445.6 million and have decreased $123.2 million since December 31, 2022. This decrease resulted primarily from cash used in operations of $71.9 million, capital expenditures of $21.0 million, cash used for acquisitions and other investments of $29.2 million, and taxes paid related to net-share settlement of equity awards of $4.8 million.

Cash held outside the U.S. at September 30, 2023 was $59.2 million, or 13.3%, of total cash and cash equivalents, compared to $58.4 million, or 15.0%, of total cash and cash equivalents at December 31, 2022. As our previously unremitted earnings have been subjected to U.S. federal income tax, we expect any repatriation of these earnings to the U.S. would not incur significant federal and state taxes. However, any repatriation of these earnings are subject to foreign withholding taxes that are estimated to result in the Company incurring tax costs in excess of the cost to obtain cash through other means.

Cash equivalents are comprised of funds held in money market instruments and are reported at their current carrying value, which approximates fair value due to the short-term nature of these instruments. We strive to minimize our credit risk by investing primarily in investment grade, liquid instruments and limiting exposure to any one issuer depending upon credit quality. See “Cash Flow” discussion below.

The changes that make up the other components of working capital not discussed above resulted from the ordinary course of business. Differences between the amounts of working capital item changes in the cash flow statement and the balance sheet changes for the corresponding items are primarily the result of foreign currency translation adjustments.

Cash Flow

The Company currently funds its operations — including working capital requirements, capital expenditures, investments and acquisitions — using cash on hand cash; cash equivalents and short-term investments; cash flow from operations, which can vary widely from quarter to quarter; and financing activities, as necessary. We expect that cash flow from operations, cash and cash equivalents, and other sources of liquidity, such as issuing equity or debt securities, subject to market conditions, will be available and sufficient to meet all foreseeable cash requirements. The following is a summary of the changes in the Company’s cash flows, followed by a brief discussion of these changes:

(in thousands)

Nine Months Ended September 30, 2023 September 30, 2022 Dollar Change
Cash flow used in operating activities $(71,893) $(52,449) $(19,444)
Cash flow provided by (used in) investing activities 130,689 (374,116) 504,805
Cash flow used in financing activities (5,215) (12,981) 7,766

Cash flow from operations

For the nine months ended September 30, 2023, cash used in operating activities was $71.9 million, and cash used in operating activities for the nine months ended September 30, 2022 was $52.4 million. The $19.4 million increase in cash flow used in operating activities during the nine months ended September 30, 2023, as compared to the same period of the prior year, is primarily due to $8.5 million of cash paid for legal settlements (see Note 18) and an increase in working capital during the nine months ended September 30, 2023.

Cash flow from investing activities

For the nine months ended September 30, 2023, cash provided by investing activities was $130.7 million, which included $180.9 million of proceeds from the sales and maturities of short-term investments, partially offset by capital expenditures of $21.0 million and cash used for investments in strategically-aligned businesses totaling $29.2 million.

For the nine months ended September 30, 2022, cash used in investing activities was $374.1 million, which included $384.4 million of purchases of short-term investments, cash used for acquisitions and other investments of $84.7 million and capital expenditures of $17.1 million, partially offset by $112.1 million of proceeds from the sales and maturities of short-term investments.

Cash flow from financing activities

For the nine months ended September 30, 2023, cash used in financing activities was $5.2 million, which primarily reflects $4.8 million of withholding taxes paid related to the net-share settlement of employee equity awards.

For the nine months ended September 30, 2022, cash used in financing activities was $13.0 million, which primarily reflects $10.2 million of withholding taxes paid related to the net-share settlement of employee equity awards and the final $2.3 million installment payment related to the acquisition of the non-controlling interest in Easyway.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements and do not utilize any “structured debt,” “special purpose” or similar unconsolidated entities for liquidity or financing purposes.

Material Cash Requirements

The Company's material cash requirements consist of the following contractual and other obligations:

Indebtedness

At September 30, 2023, we had $460 million of outstanding 0% convertible notes that mature in November 2026. Management may consider pursuing additional long-term financing if it is appropriate in light of cash requirements for operations or other strategic opportunities, which could result in higher financing costs.

Purchase Commitments

We have purchase commitments under legally enforceable agreements for goods and services with defined terms as to quantity, price and timing of delivery. In addition to ordinary purchase commitments, as of September 30, 2023, the Company had approximately $2.7 million of purchase commitments for inventory as a result of the termination of a manufacturing services agreement (refer to Note 4).

Leases

The Company had operating and financing lease obligations (inclusive of interest) of $111.3 million at September 30, 2023, primarily related to real estate and equipment leases, of which approximately $4.0 million in payments are expected over the remainder of 2023.

Dussur

In March 2022, Dussur and 3D Systems signed an agreement to form a joint venture intended to expand the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The joint venture is to enable the development of Saudi Arabia's domestic additive manufacturing production capabilities, consistent with the Kingdom’s ‘Vision 2030,’ which is focused on diversification of the economy and long-term sustainability. In February 2023, the Company became a shareholder in the joint venture and now owns 49% of its common stock. 3D Systems was committed to an initial investment of approximately $6.5 million of cash into the joint venture, all of which has been funded as of September 30, 2023. Additional future investments in the joint venture are contingent upon the achievement of certain milestones by the joint venture. The future impact that participation in the joint venture will have on the Company’s financial position and cash flows is not expected to be material other than any potential cash outflow(s) that may be required to fund contingent investments.

Sources of Funding to Satisfy Material Cash Requirements

The Company believes that it has the financial resources needed to meet its cash requirements during the next twelve months. Cash requirements for periods beyond the next twelve months will depend on, among other things, the Company’s profitability and its ability to manage working capital requirements.

Other Contractual Commitments

Convertible Notes

As of September 30, 2023, we were in compliance with all covenants of the outstanding 0% convertible notes due November 2026.

Indemnification

In the normal course of business, we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement that may be made by third parties and arise from the use of our products. Historically, costs related to these indemnification provisions have not been significant. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.

To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences, when the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors’ and officers’ insurance coverage that may enable us to recover future amounts paid, subject to a deductible and to the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.

Critical Accounting Estimates

Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and assumptions that affect the reported amounts of our assets, liabilities, revenues, costs and expenses, as well as related disclosures. On an ongoing basis, we evaluate and reassess our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.

Regenerative Medicine Earnout Payments and Performance-Based Stock Units

In connection with the acquisition of Volumetric on December 1, 2021, the Company could be required to pay up to $355.0 million in earnout payments to Volumetric’s former owners (“Sellers”) based upon the achievement of up to seven non-financial milestones. Each of the non-financial milestones, which individually triggers a specific earnout payment if achieved prior to an agreed upon date of either December 31, 2030 or December 31, 2035, is based upon specific advances in regenerative medicine related to lungs or tissue organs. For each milestone, payment is only due to the extent that the Sellers continue to be employed by the Company at the time that a milestone is achieved. As the earnout payments require the continued employment of certain of the Sellers, the Company recognizes each individual earnout payment as compensation expense over the period commencing on the date that the related milestone is deemed probable of achievement through the anticipated date of achievement.

In addition, the Company has granted performance-based stock units ("PSUs") with vesting terms that are based upon four individually-measured, non-financial milestones to other employees who work on advancements in regenerative medicine related to lungs and tissue organs — the RegMed Awards. The RegMed Awards associated with each individual milestone are recognized as compensation expense over the period commencing on the date that the respective milestone is deemed probable of being met through the anticipated date of achievement.

As the milestones that trigger the Volumetric Earnout payments and the vesting of the RegMed Awards are (1) based upon scientific and technological advancements that are expected to require multiple years of R&D to achieve and (2) subject to significant known and unknown risks and uncertainties, management must apply significant assumptions and judgment at each balance sheet date to assess both the probability of achievement and expected timing of achievement. A change in management’s assumptions or estimates regarding the probability and/or timing of achievement of a milestone in connection with management’s quarterly reassessment can materially impact the amount of compensation expense recognized for the respective and future periods as follows:

  • A change in assumptions that results in a milestone first being deemed probable of achievement will result in the recognition of incremental compensation expense in the Company’s consolidated statement of operations;
  • A change in assumption regarding the timing of achievement of a milestone will result in the acceleration or deceleration of the recognition of future compensation expense, as well as the potential recognition of an expense catch-up or reversal adjustment in the period of change; and/or
  • A change in assumption that results in a milestone no longer being deemed probable of achievement will result in a full reversal of previously recognized expense.

Prior to the quarter ended September 30, 2023, the Company recognized compensation expense related to (1) one Volumetric milestone-based payment, for which the potential amount due to the sellers would be $65,000, and (2) one PSU milestone (“the RegMed Awards”), for which the aggregate grant date fair value of the outstanding and unvested awards was $4,773 as of June 30, 2023, as the related milestone was deemed probable of achievement. During the quarter ended June 30, 2023, as a result of the Company's decision to reduce budgeted funding related to the research and development efforts required to achieve the milestone, the estimated timing for achievement of both the Volumetric milestone and the PSU milestone shifted from the end of fiscal year 2025 to the end of fiscal year 2026. During the quarter ended September 30, 2023, the Company decided to further reduce its budgeted funding for the research and development related to the Volumetric Earnout and RegMed Award milestone, which resulted in the Company concluding that it is no longer probable that the milestone will be achieved by the end of the term of the Volumetric Earnout arrangement or prior to the expiration of the RegMed Awards. In concluding that the Volumetric and RegMed Award milestone would no longer be achieved, the Company reversed all of the previously accrued compensation expense, one half of which was expected to be settled with common shares, which had an income statement impact of $21.5 million and $18.4 million for the three and nine-months ended September 30, 2023, respectively.

As a result of the reversal of all previously recognized expense during the quarter ended September 30, 2023, the Company has not recognized any compensation expense related to (1) the $355.0 million of Volumetric earnout payments and (2) the outstanding RegMed Awards with an aggregate grant date fair value of $19.1 million. This is because none of the related non-financial milestones are deemed probable of achievement as of September 30, 2023. Changes to management’s assumptions regarding the probability and/or timing of achievement of these milestones could significantly increase the amount of compensation expense recognized by the Company in the future.

With the exception of the change in estimate impacting the expense and liability recognized for the Volumetric earnout and the expense recognized for the RegMed Awards, there have been no other material changes to the Critical Accounting Estimates described in our 2022 Form 10-K that have had a material impact on our condensed consolidated financial statements and/or the related notes during the three and nine months ended September 30, 2023. However, recent events, including the Company's recently announced restructuring plan and the recent trading price of the Company's common stock, could result in changes to certain of the Company's past estimates, assumptions, and judgments underlying the "Critical Accounting Estimates" described in our 2022 Form 10-K. Any future changes in those estimates, assumptions and judgments could potentially have a material near-term impact on the Company's reported results. Refer to the discussion that follows for details regarding our historical Critical Accounting Estimates for which we have identified a higher potential for a change in the underlying assumptions, judgments and estimates and, accordingly, a higher potential for a material near-term impact on the Company's reported results.

Goodwill and Other Long-Lived Assets, Including Intangible Assets

Long-Lived Assets, Including Intangible Assets

We review long-lived assets (or asset groups), including intangible assets subject to amortization, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset (or asset group) may not be recoverable. We assess the recoverability of the carrying value of assets (or asset groups) held for use based upon a review of undiscounted projected cash flows. Impairment losses, where identified, are measured as the excess of the carrying value of a long-lived asset (or asset group) over its estimated fair value, as determined using discounted projected cash flows.

As the Company's latest phase of its multi-faceted restructuring initiative that was announced on October 25, 2023 contemplates the execution of new strategic actions that may be taken with respect to certain of the Company’s previously acquired businesses and/or other asset groups, certain asset groups could become subject to impairment tests triggered by (1) an adverse change in the extent or manner in which the long-lived asset (or asset group) is being used, (2) a current expectation that it is more likely than not that the long-lived asset (or asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life, or (3) other factors triggered by the Company's restructuring initiative. If required, a quantitative impairment test related to any of our asset groups could result in the recognition of a material impairment charge.

Goodwill

Goodwill represents the purchase price paid in excess of the fair value of net tangible and intangible assets acquired in a business combination. We review goodwill for impairment annually and, between annual impairment assessments, when circumstances indicate that the likelihood of an impairment is greater than 50%. Such circumstances may include a significant adverse change in the business climate for one of our reporting units or a decision to dispose of a reporting unit or a significant portion of a reporting unit. The test for goodwill impairment compares the fair value of each of our reporting units to its respective carrying value. This process requires a significant level of estimation and use of judgment by management – particularly to (1) estimate the fair value of each of our reporting units and (2) determine the carrying of each of our reporting units, since we do not maintain separate balance sheets for our reporting units.

We estimate the fair value of our reporting units based primarily on the discounted projected cash flows of their underlying operations, which requires us to make assumptions about estimated cash flows, including long-term revenue and expense forecasts, profit margins, discount rates and terminal growth rates. We develop these assumptions based on the market risks unique to each reporting unit. We separately use reasonable and consistent allocation methodologies and approaches to allocate asset and liability balances to our reporting units when an account balance is not directly attributable to a specific reporting unit.

We conducted our annual goodwill impairment tests for the years ended December 31, 2022 and 2021 as of November 30, 2022 and 2021, respectively, and concluded that there was no goodwill impairment. During the quarter ended September 30, 2023, the Company experienced a significant decline in its market capitalization as a result of a decrease in its stock price, and during the month ended September 30, 2023, the Company’s market capitalization fell slightly below its consolidated stockholders’ equity balance. We do not consider this to constitute a sustained decrease in the Company’s stock price as of September 30, 2023. Furthermore, the Company performed a qualitative goodwill impairment assessment as of September 30, 2023 and concluded that it is not more likely than not that the fair value of either of its reporting units is less than the reporting unit’s carrying value as of September 30, 2023. As a result, we concluded that no triggering event had occurred that would require the Company to perform a quantitative goodwill impairment test for either of its two reporting units as of September 30, 2023. However, the Company’s market capitalization has declined further since September 30, 2023, and if such a decline results in the estimated fair value of either of our reporting units being lower than the respective reporting unit’s carrying value, the Company would need to record a non-cash goodwill impairment charge, which could be material, in a future period – including as of our upcoming annual impairment testing date of November 1, 2023 (reflecting our annual goodwill impairment testing date commencing as of the current fiscal year).

Forward-Looking Statements

Certain statements made in this Form 10-Q that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates,” or “plans” or the negative of these terms or other comparable terminology.

Forward-looking statements are based upon management’s beliefs, assumptions and current expectations concerning future events and trends, using information currently available, and are necessarily subject to uncertainties, many of which are outside our control. Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as, a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. A number of important factors could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. These factors include without limitation:

  • impacts on our business resulting from macroeconomic events, including the Russia-Ukraine war and other geopolitical risks, recession, supply chain disruptions and foreign exchange volatility;
  • our ability to deliver products that meet changing technology and customer needs;
  • our ability to identify strategic acquisitions, to integrate such acquisitions into our business without disruption and to realize the anticipated benefits of such acquisitions;
  • impacts of future write-offs or write-downs of goodwill and intangible assets;
  • the concentration of revenue and credit risk exposure from our largest customer;
  • our ability to acquire and enforce intellectual property rights and defend such rights against third party claims;
  • our ability to protect our intellectual property rights and confidential information, including our digital content, from third-party infringers or unauthorized copying, use or disclosure;
  • failure of our information technology infrastructure or inability to protect against cyber-attack;
  • our ability to predict quarterly sales and manage product inventory due to uneven sales cycles;
  • our ability to generate net cash flow from operations;
  • our ability to service our debt and ability to raise funds necessary to settle conversions of the Notes in cash, repay the Notes at maturity, or repurchase the Notes in the case of a fundamental change;
  • our ability to remediate material weaknesses in our internal controls over financial reporting and maintain effective internal controls;
  • fluctuations in our gross profit margins, operating income or loss and/or net income or loss;
  • our ability to efficiently conduct business outside the U.S.;
  • our dependence on our supply chain for components and sub-assemblies used in our 3D printers and other products and for raw materials used in our print materials;
  • our ability to manage the costs and effects of litigation, investigations or similar matters involving us or our subsidiaries;
  • our ability to avoid and manage product quality problems that could result in decreased sales and operating margin, product returns, product liability, warranty or other claims;
  • our ability to retain our key employees and to attract and retain new qualified employees, while controlling our labor costs;
  • our ability to successfully develop and commercialize regenerative medicine products ourselves, or in conjunction with development partners;
  • disruption in our management information systems for inventory management, distribution, and other key functions;
  • compliance with U.S. and other anti-corruption laws, data privacy laws, trade controls, economic sanctions, and similar laws and regulations;
  • our ability to maintain our status as a responsible contractor under federal rules and regulations;
  • changes in, or interpretation of, tax rules and regulations; and
  • the other factors discussed in the reports we file with or furnish to the SEC from time to time, including the risks and important factors set forth in additional detail in Item 1A. “Risk Factors” in the 2022 Form 10-K.

Readers are cautioned not to place undue reliance on our forward-looking statements. The forward-looking statements included herein are made only as of the date of this Form 10-Q, and we undertake no obligation to publicly update or revise any forward-looking statement made by us or on our behalf, whether as a result of new information, future developments, subsequent events or circumstances or otherwise, except as required by law. All subsequent written or oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

Market risk

As filed, 352 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

For a discussion of market risks at December 31, 2022, refer to Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” in our 2022 Form 10-K. During the three and nine months ended September 30, 2023, there were no material changes or developments that would materially alter the market risk assessment performed as of December 31, 2022.

Controls and procedures

As filed, 6,836 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

As of September 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) pursuant to Rules 13a-15 and 15d-15 under the Exchange Act. These controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, in a manner to allow timely decisions regarding required disclosures. Based on this evaluation, management has concluded that our disclosure controls and procedures were not effective as of September 30, 2023 due to the following two material weaknesses in internal control over financial reporting:

  • We did not design or maintain effective controls in response to the risks of material misstatement, including designing and maintaining formal accounting policies, procedures, and controls over significant accounts and disclosures to achieve complete, accurate and timely financial accounting, reporting and disclosures, with respect to: (1) revenue, receivables and deferred revenue, including the input of executed contract terms into the Company’s information systems that perform revenue recognition; and (2) the review of internally prepared reports and analyses utilized in the financial closing process.

Notwithstanding the existence of the material weaknesses described above, management believes that the condensed consolidated financial statements included in this Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows, as of and for the periods presented, in conformity with GAAP.

Management’s Plan for Remediation

The material weaknesses described above were initially identified at December 31, 2020 and continued to exist at December 31, 2022. However, as a result of the remediation plan we commenced in January 2021, the number of control deficiencies that aggregated into the material weaknesses at December 31, 2022 were significantly reduced as compared to December 31, 2020. The remediation plan we began in January 2021 is designed to improve our internal control over financial reporting and remediate the related control deficiencies that led to these material weaknesses. In response to these deficiencies, management, with the oversight of the Audit Committee of the Board of Directors, has identified and implemented steps to remediate the material weaknesses.

During the year ended December 31, 2022, the Company completed the implementation of the following remedial measures designed to address the material weaknesses and to continue to improve our internal control over financial reporting.

  • Established a formal controls governance committee in the first quarter of 2022 to manage and enhance the oversight and execution of internal controls. The controls governance committee consists of members of senior leadership, which meets monthly or more frequently as needed.
  • Retained an outside firm with expertise in the design and execution of internal controls over financial reporting to examine our control design, perform a root cause analysis as to why certain controls have not been and continue to not be properly executed, and to advise on changes in the design of our controls and procedures and implementation of our remediation activities.
  • Enhanced the global control environment, including testing in 2022 of a significant number of additional business process and information technology controls.
  • Implemented software to manage and administer account reconciliations.
  • Revamped and expanded our internal disclosure processes to provide greater representation across functions and improve opportunities to identify matters requiring accounting disposition or disclosures.
  • Implemented software enhancements, including a tax reporting solution for our tax provision process.
  • Redesigned controls related to the accounting for the income tax process.
  • Engaged a third party to review our quarterly and annual tax calculations.
  • Hired additional experienced resources with backgrounds in income tax accounting.

Our remaining internal control remediation efforts are expected to include the following:

  • Design and implementation of enhanced policies, procedures and controls relating to our revenue recognition and our closing and financial reporting process.
  • Redesign of existing management review controls, including the input of executed contract terms into the Company’s information systems that perform revenue recognition.
  • Hire and retain additional staff with sufficient experience and knowledge in GAAP financial reporting matters and internal control over financial reporting.
  • Train appropriate personnel in the effective design and execution of our enhanced policies, procedures and controls, including the importance of the ongoing, consistent effective execution of such procedures and controls.
  • Initiation of a robust finance transformation initiative with dedicated resources tasked to create a more efficient close process and implement key technologies to enable a more mature and automated control environment.

We are committed to the remediation of all material weaknesses and expect to successfully implement enhanced control processes. However, as we continue to evaluate, and work to improve our internal control over financial reporting, management may determine that additional measures to address control deficiencies or modifications to the remediation plan are necessary. Therefore, we cannot assure you when we will remediate such weaknesses, nor can we be certain that additional actions will not be required or the costs of any such additional actions. Moreover, we cannot assure you that additional material weaknesses will not arise in the future.

Changes in Internal Control Over Financial Reporting

We are in the process of implementing certain changes to our internal controls to remediate the material weaknesses described above. Except as noted above, there were no changes in the Company’s internal control over financial reporting during the three months ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Risk factors

As filed, 132 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There are no material changes to the risk factors previously disclosed in response to Item 1A, “Risk Factors” in our 2022 Form 10-K.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-07-01 to 2023-09-30$123.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2023-01-01 to 2023-09-30$373.2mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-07-01 to 2023-09-30$68.4mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2023-01-01 to 2023-09-30$220.8mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2023-07-01 to 2023-09-30$55.4mus-gaap:GrossProfit
Gross profit9 months2023-01-01 to 2023-09-30$152.5mus-gaap:GrossProfit
Research and development3 months2023-07-01 to 2023-09-30$22.0mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2023-01-01 to 2023-09-30$67.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2023-07-01 to 2023-09-30$33.4mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2023-01-01 to 2023-09-30$150.6mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-07-01 to 2023-09-30−$13.6mus-gaap:OperatingIncomeLoss
Operating income9 months2023-01-01 to 2023-09-30−$78.7mus-gaap:OperatingIncomeLoss
Income tax3 months2023-07-01 to 2023-09-30$174.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2023-01-01 to 2023-09-30$404.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-07-01 to 2023-09-30−$11.7mus-gaap:NetIncomeLoss
Net income9 months2023-01-01 to 2023-09-30−$70.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-07-01 to 2023-09-30−$0.09us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2023-01-01 to 2023-09-30−$0.54us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-07-01 to 2023-09-30−$0.09us-gaap:EarningsPerShareBasic
Basic EPS9 months2023-01-01 to 2023-09-30−$0.54us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-07-01 to 2023-09-30130,263,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2023-01-01 to 2023-09-30129,780,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2023-01-01 to 2023-09-30−$71.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2023-01-01 to 2023-09-30$21.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-09-30$445.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-09-30$739.7mus-gaap:AssetsCurrent
Total assetsAt period end2023-09-30$1.39bnus-gaap:Assets
Current liabilitiesAt period end2023-09-30$137.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-09-30$691.3mus-gaap:Liabilities
Long-term debtAt period end2023-09-30$451.5mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2023-09-30$699.5mus-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Source: SEC EDGAR, the filing index for accession 0000910638-23-000025. Last ingested by Listed: Nov 15, 2026, 00:01 ET. Listed shows no prices and gives no investment advice.